Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study-Reference-Cited by-同舟云学术

Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study

Published:2023-04 Issue: Volume:27 Page:100592
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Gijtenbeek Rolof G.P.,Damhuis Ronald A.M.,van der Wekken Anthonie J.,Hendriks Lizza E.L.^ORCID,Groen Harry J.M.,van Geffen Wouter H.^ORCID

Publisher

Elsevier BV

Subject

Health Policy,Oncology,Internal Medicine

Reference47 articles.

1. Association of molecular status and metastatic organs at diagnosis in patients with stage IV non-squamous non-small cell lung cancer;Kuijpers;Lung Cancer,2018

2. Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis;Kuan;Br J Cancer,2015

3. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non–small-cell lung cancer in the USA;Li;PLoS One,2019

4. Osimertinib in untreated EGFR -mutated advanced non–small-cell lung cancer;Soria;N Engl J Med,2018

5. AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations;Lu;J Clin Oncol,2022

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations;Hereditary Cancer in Clinical Practice;2024-08-19

2. Representing mutations for predicting cancer drug response;Bioinformatics;2024-06-28

3. Current status of molecular diagnostics for lung cancer;Exploration of Targeted Anti-tumor Therapy;2024-06-27

4. Unraveling biological processes and EGFR pathway regulation by the protein tyrosine phosphatase PTPRH in non-small cell lung cancer;2024-06-16

5. CRISPR/Cas13a-based supersensitive circulating tumor DNA assay for detecting EGFR mutations in plasma;Communications Biology;2024-05-28